AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Medical Devices

$BDMD

Baird Medical Investment Holdings Ltd

Insider trades
Price · $BDMDvia TradingView
AI sentiment · 7d1 articles
AUG 4net (bullish − bearish)AUG 10
Bullish
1
Neutral
0
Bearish
0
Insider · 30dAll trades →

No SEC Form 4 filings for $BDMD in the last 30 days.

See all $BDMD insider activity →
Top stories · $BDMDMore →
AUG 10·finanznachrichten.deMed

Baird Medical Investment Holdings Ltd.: Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally

Baird Medical Investment Holdings (NASDAQ: BDMD) said it signed a strategic cooperation agreement with Alpmed, a China-based IRE technology company, to develop and commercialize next-generation irreversible electroporation ablation. The firms plan a U.S. FDA 510(k) submission by end-2026 and potential clearance in 2027 for a soft-tissue tumor device.

See more news on $BDMD →

BDMD sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning BDMD (Baird Medical Investment Holdings Ltd). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

What's driving BDMD

  • The deal creates a concrete regulatory timeline and expands BDMD beyond its MWA base into IRE, potentially improving medium-term growth optionality.

    finanznachrichten.de · Aug 10, 2026

alphai scores every news story that mentions BDMD with an AI model for sentiment and relevance, and aggregates insider trades from Baird Medical Investment Holdings Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BDMD

Score
AUG 10$BDMDMedfinanznachrichten.de

Baird Medical Investment Holdings Ltd.: Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally

Baird Medical Investment Holdings (NASDAQ: BDMD) said it signed a strategic cooperation agreement with Alpmed, a China-based IRE technology company, to develop and commercialize next-generation irreversible electroporation ablation. The firms plan a U.S. FDA 510(k) submission by end-2026 and potential clearance in 2027 for a soft-tissue tumor device.

3 min read

Related tickers

More in Medical Devices